Allergy Thera. Share News (AGY)

Allergy Therapeutics dust mite study yields positive results

Pharmaceutical group Allergy Therapeutics has announced positive results from a clinical study for the treatment of house dust mite allergy. Results of the observational one-year follow-up study of Acarovac Plus showed that there were no adverse effects to the tolerability of the product, while ther

Allergy Therapeutics Gets Good Results From Acarovac Plus Study

Allergy Therapeutics To Host Allergy Conference In Amsterdam

Allergy Therapeutics Resumes Allergy Treatment US Clinical Programme

Allergy Therapeutics buys Alerpharma for 3.8m euros

Specialty pharmaceutical company Allergy Therapeutics said on Friday that it has agreed to buy Alerpharma SA for an initial consideration of €3.8m. Alerpharma wholly owns the Spanish-based allergy immunotherapy company Instituto de Immunologia y Alergia (Inmunal),which is a spin-out of biopharmaceut

Allergy Therapeutics Acquires Alerpharma For Up To EUR5.8 Million

UK MIDDAY BRIEFING: The Man From The Pru To Leave On High Note

UK WINNERS & LOSERS: Oil Stocks, Gold Miners Hit By Price Weakness

Allergy Therapeutics Raises GBP20.8 Million In Share Placing (ALLISS)

Allergy Therapeutics Ups Profit, Revenue, Market Share In First Half

Allergy Therapeutics To Post 4% Rise In First-Half Revenue

Allergy Therapeutics Extends Convertible Loan With Abbott Labs' CFR

Allergy Therapeutics Profit Up, Optimistic For Future On US Prospects

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead